Nonclinical toxicological evaluation of occidiofungin, a unique glycolipopeptide antifungal

Int J Toxicol. 2012 Jul-Aug;31(4):326-36. doi: 10.1177/1091581812445185. Epub 2012 Jun 11.

Abstract

Occidiofungin, a glycolipopeptide obtained from the liquid culture of Burkholderia contaminans MS14, has been identified as a novel fungicide. The present study was designed to initially assess the in vitro toxicity in a rat hepatoma (H4IIE) cell line and acute toxicological effects of occidiofungin using a mouse model. In vitro toxicity was observed in all variables at 5 μmol/L. B6C3F1 mice were given single and repeat doses of occidiofungin up to 20 mg/kg. Key effects were a reduction in body and organ weights. However, no significant decrease in body weight was noted at a dose of 1 mg/kg, which is comparable to the dose level of other cyclic glycopeptide antifungal agents currently approved for human use. Microscopic examination of treated mice did not identify any signs of organ-specific toxicity at the dose levels tested.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antifungal Agents / pharmacology*
  • Bacterial Toxins / pharmacology*
  • Body Weight / drug effects
  • Burkholderia / metabolism
  • Cell Line, Tumor
  • Dose-Response Relationship, Drug
  • Drug Evaluation, Preclinical
  • Female
  • Glycopeptides / pharmacology*
  • Mice
  • Mice, Inbred C57BL
  • Organ Size / drug effects
  • Peptides, Cyclic / pharmacology*
  • Rats
  • Toxicity Tests, Acute

Substances

  • Antifungal Agents
  • Bacterial Toxins
  • Glycopeptides
  • Peptides, Cyclic
  • occidiofungin